
- /
- Supported exchanges
- / KO
- / 207940.KO
Samsung Biologics Co Ltd (207940 KO) stock market data APIs
Samsung Biologics Co Ltd Financial Data Overview
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Samsung Biologics Co Ltd data using free add-ons & libraries
Get Samsung Biologics Co Ltd Fundamental Data
Samsung Biologics Co Ltd Fundamental data includes:
- Net Revenue: 4 898 692 M
- EBITDA: 2 204 527 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-23
- EPS/Forecast: 4020.49
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Samsung Biologics Co Ltd News

Samsung Biologics reports first quarter 2025 financial results
Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by enhance...


Samsung Biologics recognized for leadership band in water security
- Company receives leadership status and A- rating for efficient water resources management - Recognition reflects Samsung Biologics' commitment to water security and implemen...

Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
Recorded Q4'24 consolidated revenue of KRW 1.26 trillion Recorded FY'24 consolidated revenue of KRW 4.55 trillion Poised for further growth with expanded capacity and new service offerings INCHEON, S...

Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabili...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.